Literature DB >> 10813118

Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography.

J G Guillem1, J Puig-La Calle, T Akhurst, S Tickoo, L Ruo, B D Minsky, M J Gollub, D S Klimstra, M Mazumdar, P B Paty, H Macapinlac, H Yeung, L Saltz, R D Finn, Y Erdi, J Humm, A M Cohen, S Larson.   

Abstract

PURPOSE: The purpose of this prospective study was to determine the ability of fluorine-18 fluorodeoxyglucose positron emission tomography to assess extent of pathologically confirmed rectal cancer response to preoperative radiation and 5-fluorouracil-based chemotherapy.
METHODS: Patients with primary rectal cancer deemed eligible for preoperative radiation and 5-fluorouracil-based chemotherapy because of a clinically bulky or tethered tumor or endorectal ultrasound evidence of T3 and/or N1 were prospectively enrolled. Positron emission tomography and CT scans were obtained before preoperative radiation and 5-fluorouracil-based chemotherapy (5,040 cGy to the pelvis and 2 cycles of bolus 5-fluorouracil with leucovorin) and repeated four to five weeks after completion of radiation and 5-fluorouracil-based chemotherapy. In addition to routine pathologic staging, detailed assessment of rectal cancer response to preoperative radiation and 5-fluorouracil-based chemotherapy was performed independently by two pathologists. Positron emission tomography parameters studied included conventional measures such as standardized uptake value (average and maximum), positron emission tomography-derived tumor volume (size), and two novel parameters: visual response score and change in total lesion glycolysis.
RESULTS: Of 21 patients enrolled, prospective data (pretreatment and posttreatment positron emission tomography, and complete pathologic assessment) were available on 15 patients. All 15 demonstrated pathologic response to preoperative radiation and 5-fluorouracil-based chemotherapy. This was confirmed in 100 percent of the cases by positron emission tomography compared with 78 percent (7/9) by CT. In addition, one positron emission tomography parameter (visual response score) accurately estimated the extent of pathologic response in 60 percent (9/15) of cases compared with 22 percent (2/9) of cases with CT.
CONCLUSIONS: This pilot study demonstrates that fluorine-18 fluorodeoxyglucose positron emission tomography imaging adds incremental information to the preoperative assessment of patients with rectal cancer. However, further studies in a larger series of patients are needed to verify these findings and to determine the value of fluorine-18 fluorodeoxyglucose positron emission tomography in a preoperative strategy aimed at identifying patients suitable for sphincter-preserving rectal cancer surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813118     DOI: 10.1007/bf02237238

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  32 in total

Review 1.  18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.

Authors:  B B Chin; R L Wahl
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

2.  Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation.

Authors:  Shane Hopkins; Marwan Fakih; Gary Y Yang
Journal:  World J Gastrointest Oncol       Date:  2010-05-15

3.  Usefulness of two independent histopathological classifications of tumor regression in patients with rectal cancer submitted to hyperfractionated pre-operative radiotherapy.

Authors:  Lukasz Liszka; Ewa Zielińska-Pajak; Jacek Pajak; Dariusz Gołka; Jacek Starzewski; Zbigniew Lorenc
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

4.  Re: Salvaging a linear staple line defect in ultra-low anterior resection.

Authors:  Y-H Ho
Journal:  Tech Coloproctol       Date:  2008-03       Impact factor: 3.781

5.  A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation.

Authors:  Jose G Guillem; David B Chessin; Jinru Shia; Arief Suriawinata; Elyn Riedel; Harvey G Moore; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

6.  Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Authors:  Jihyun Park; Kyoung Jin Chang; Young Seok Seo; Byung Hyun Byun; Joon Ho Choi; Hansol Moon; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2014-08-01

7.  Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay.

Authors:  Jung Wook Huh; Yoon Ah Park; Eun Joo Jung; Kang Young Lee; Ji Eun Kwon; Seung-Kook Sohn
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

8.  Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation: a first step towards a molecular surrogate marker for neoadjuvant treatment in colorectal cancer.

Authors:  Peter Kienle; Moritz Koch; Frank Autschbach; Axel Benner; Martina Treiber; Michael Wannenmacher; Magnus von Knebel Doeberitz; Markus Büchler; Christian Herfarth; Jürgen Weitz
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

9.  Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy.

Authors:  Leyo Ruo; Satish Tickoo; David S Klimstra; Bruce D Minsky; Leonard Saltz; Madhu Mazumdar; Philip B Paty; W Douglas Wong; Steven M Larson; Alfred M Cohen; Jose G Guillem
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

10.  Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Authors:  David W Dietz; Farrokh Dehdashti; Perry W Grigsby; Robert S Malyapa; Robert J Myerson; Joel Picus; Jon Ritter; Jason S Lewis; Michael J Welch; Barry A Siegel
Journal:  Dis Colon Rectum       Date:  2008-08-06       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.